Document Detail


AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial.
MedLine Citation:
PMID:  21419704     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Gene transfer of glutamic acid decarboxylase (GAD) and other methods that modulate production of GABA in the subthalamic nucleus improve basal ganglia function in parkinsonism in animal models. We aimed to assess the effect of bilateral delivery of AAV2-GAD in the subthalamic nucleus compared with sham surgery in patients with advanced Parkinson's disease.
METHODS: Patients aged 30-75 years who had progressive levodopa-responsive Parkinson's disease and an overnight off-medication unified Parkinson's disease rating scale (UPDRS) motor score of 25 or more were enrolled into this double-blind, phase 2, randomised controlled trial, which took place at seven centres in the USA between Nov 17, 2008, and May 11, 2010. Infusion failure or catheter tip location beyond a predefined target zone led to exclusion of patients before unmasking for the efficacy analysis. The primary outcome measure was the 6-month change from baseline in double-blind assessment of off-medication UPDRS motor scores. This trial is registered with ClinicalTrials.gov, NCT00643890.
FINDINGS: Of 66 patients assessed for eligibility, 23 were randomly assigned to sham surgery and 22 to AAV2-GAD infusions; of those, 21 and 16, respectively, were analysed. At the 6-month endpoint, UPDRS score for the AAV2-GAD group decreased by 8·1 points (SD 1·7, 23·1%; p<0·0001) and by 4·7 points in the sham group (1·5, 12·7%; p=0·003). The AAV2-GAD group showed a significantly greater improvement from baseline in UPDRS scores compared with the sham group over the 6-month course of the study (RMANOVA, p=0·04). One serious adverse event occurred within 6 months of surgery; this case of bowel obstruction occurred in the AAV2-GAD group, was not attributed to treatment or the surgical procedure, and fully resolved. Other adverse events were mild or moderate, likely related to surgery and resolved; the most common were headache (seven patients in the AAV2-GAD group vs two in the sham group) and nausea (six vs two).
INTERPRETATION: The efficacy and safety of bilateral infusion of AAV2-GAD in the subthalamic nucleus supports its further development for Parkinson's disease and shows the promise for gene therapy for neurological disorders.
FUNDING: Neurologix.
Authors:
Peter A LeWitt; Ali R Rezai; Maureen A Leehey; Steven G Ojemann; Alice W Flaherty; Emad N Eskandar; Sandra K Kostyk; Karen Thomas; Atom Sarkar; Mustafa S Siddiqui; Stephen B Tatter; Jason M Schwalb; Kathleen L Poston; Jaimie M Henderson; Roger M Kurlan; Irene H Richard; Lori Van Meter; Christine V Sapan; Matthew J During; Michael G Kaplitt; Andrew Feigin
Related Documents :
8792904 - Course of illness and pattern of recurrences in patients with affective disorders durin...
21349484 - Effect of two-day atorvastatin pretreatment on long-term outcome of patients with stabl...
21493314 - Efficacy of the combination of intraoperative cold saline-soaked gauze compression and ...
3670614 - Dopamine agonist therapy for neglect in humans.
17445634 - Treatment of postoperative ileus after bowel surgery with low-dose intravenous erythrom...
22954974 - Pituitary dysfunction in survivors of spontaneous subarachnoid hemorrhage of anterior c...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Lancet. Neurology     Volume:  10     ISSN:  1474-4465     ISO Abbreviation:  Lancet Neurol     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-03-25     Completed Date:  2011-06-15     Revised Date:  2014-08-15    
Medline Journal Info:
Nlm Unique ID:  101139309     Medline TA:  Lancet Neurol     Country:  England    
Other Details:
Languages:  eng     Pagination:  309-19     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Elsevier Ltd. All rights reserved.
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00643890
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Double-Blind Method
Female
Gene Transfer Techniques*
Genetic Therapy / methods*
Glutamate Decarboxylase / genetics*
Humans
Male
Middle Aged
Parkinson Disease / therapy*
Subthalamic Nucleus / physiopathology
Treatment Outcome
Chemical
Reg. No./Substance:
EC 4.1.1.15/Glutamate Decarboxylase
Comments/Corrections
Comment In:
Lancet Neurol. 2011 Apr;10(4):290-1   [PMID:  21419705 ]
Nat Rev Neurol. 2011 May;7(5):241   [PMID:  21487423 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mycobacterium tuberculosis attenuated by multiple deletions of rpf genes effectively protects mice a...
Next Document:  Ultrasonography and renography to visualize upper urinary tract in children with meningomyelocele - ...